Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 7/20 | 0.40 |
| ▸ | FLT1 | P17948 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106240 | 0.78 | VNN1 (0.49) | VNN1KDRAURKARPS6KB1USP1 | |
| SCHEMBL445351 | 0.78 | AURKA (0.38) | VNN1AURKARPS6KB1HDAC1HDAC6 | |
| SCHEMBL6104003 | 0.78 | CYP1A2 (0.49) | VNN1KDRAURKARPS6KB1USP1 | |
| SCHEMBL448014 | 0.77 | MEN1 (0.42) | VNN1KDRRETHDAC1 | |
| SCHEMBL6105748 | 0.76 | VNN1 (0.46) | VNN1KDRAURKARPS6KB1AURKB | |
| SCHEMBL6107998 | 0.76 | VNN1 (0.48) | VNN1KDRAURKARPS6KB1AURKB | |
| SCHEMBL6106129 | 0.75 | VNN1 (0.50) | VNN1AURKARPS6KB1AURKB | |
| SCHEMBL449066 | 0.73 | HDAC6 (0.45) | VNN1KDRFLT1AURKARPS6KB1 | |
| SCHEMBL448286 | 0.73 | CYP3A4 (0.41) | VNN1KDRRPS6KB1HDAC1HDAC8 | |
| SCHEMBL6104170 | 0.72 | CDC7 (0.43) | VNN1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | claimed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | VNN1 1373/4885KDR 15/4885FLT1 9/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | VNN1 1132/4885KDR 13/4885FLT1 15/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | VNN1 1287/4885KDR 8/4885FLT1 11/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | VNN1 1373/4885KDR 15/4885FLT1 9/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | VNN1 1287/4885KDR 8/4885FLT1 11/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | VNN1 1132/4885KDR 13/4885FLT1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.